AbCellera And Lilly Expand Collaboration To Develop Antibody Medicines

Author: Benzinga Newsdesk | July 31, 2024 09:11am

AbCellera (NASDAQ:ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera's COVID-19 antibody program.

AbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the U.S. Food and Drug Administration for two COVID-19 antibody therapies co-developed by the companies.

Posted In: ABCL LLY